Gsk (GSK) Non-Current Deferred Tax Liability (2009 - 2026)

Gsk (GSK) has 10 years of Non-Current Deferred Tax Liability data on file, last reported at $387.1 million in Q4 2025.

• In Q4 2025, Non-Current Deferred Tax Liability fell 21.05% year-over-year to $387.1 million; the TTM figure through Dec 2025 stood at $387.1 million (down 21.05% YoY), while the FY2025 annual figure was $387.1 million, down 21.05% from the prior year.
• Non-Current Deferred Tax Liability fell to $387.1 million in Q4 2025, from $490.3 million in the prior quarter.
• Across five years, Non-Current Deferred Tax Liability topped out at $4.8 billion in Q4 2021 and bottomed at $339.0 million in Q4 2022.
• A 5-year average of $1.3 billion and a median of $387.1 million in 2025 frame the typical range for Non-Current Deferred Tax Liability.
• Annual changes were most pronounced in 2022 — Non-Current Deferred Tax Liability tumbled 92.93% — and 2024, when it advanced 27.02%.
• Year by year, Non-Current Deferred Tax Liability stood at $4.8 billion in 2021, then sank by 92.93% to $339.0 million in 2022, then grew by 13.87% to $386.0 million in 2023, then climbed by 27.02% to $490.3 million in 2024, then dropped by 21.05% to $387.1 million in 2025.
• The last three Non-Current Deferred Tax Liability figures came in at $387.1 million (Q4 2025), $490.3 million (Q4 2024), and $386.0 million (Q4 2023), per Business Quant data.

Peer Comparison